HighVista Strategies LLC Has $2.87 Million Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

HighVista Strategies LLC trimmed its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 6.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,459 shares of the company’s stock after selling 7,330 shares during the quarter. HighVista Strategies LLC owned about 0.24% of Enliven Therapeutics worth $2,872,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ELVN. FMR LLC increased its position in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the period. First Turn Management LLC bought a new stake in Enliven Therapeutics in the second quarter valued at about $9,657,000. Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth about $5,998,000. Marshall Wace LLP bought a new position in Enliven Therapeutics during the 2nd quarter worth approximately $4,489,000. Finally, Walleye Capital LLC bought a new stake in Enliven Therapeutics in the third quarter valued at approximately $2,539,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $24.43 on Tuesday. The business has a 50-day moving average of $26.80 and a 200-day moving average of $24.14. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.

Insider Activity at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $27.50, for a total transaction of $75,075.00. Following the completion of the transaction, the chief executive officer now owns 1,033,793 shares in the company, valued at approximately $28,429,307.50. This trade represents a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 129,195 shares of company stock valued at $3,581,772. Insiders own 29.20% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.